<cite id="su0oc"></cite><rp id="su0oc"></rp>

    1. <tt id="su0oc"></tt>

        1. <tt id="su0oc"></tt>
          <source id="su0oc"><progress id="su0oc"></progress></source>

          世衛組織批準“Covishield”疫苗在尼泊爾的緊急使用

          2021年03月03日 08:38  點擊:[]


          世衛組織批準“Covishield”疫苗在尼泊爾的緊急使用

                                                          時間:2021年2月17日 刊于:共和報

          加德滿都,2月17日訊:目前在尼泊爾投入使用的Covishield疫苗已經得到世界衛生組織的批準。該組織周一允許尼泊爾緊急使用Covishield,一種由印度血清研究所生產的疫苗,是與牛津大學和阿斯利康制藥公司合作開發的兩種疫苗之一。

          世衛組織還批準了阿斯利康和一家韓國公司生產的疫苗。12月31日早些時候,世衛組織批準緊急使用輝瑞疫苗。在此之前,該組織于12月31日批準緊急使用輝瑞疫苗。印度政府向尼泊爾提供的100萬劑科維希爾德疫苗由印度血清研究所生產。它是由牛津大學和阿斯利康聯合開發的。該疫苗從1月17日開始在尼泊爾的第一階段發放給一線衛生工作者、清潔工和醫院工作人員,在藥監部批準在尼泊爾緊急使用后,隨后發放給記者、聯合國機構和外交使團的工作人員。

          現在政府已開始為公務員、地方政府民選代表、銀行雇員、保健志愿者、救護車司機、靈車司機和從事尸體管理的工作人員接種疫苗,并正準備從3月第二周起在社區一級為55歲以上的老年人接種疫苗。經世衛組織批準,在“新冠肺炎疫苗實施計劃”(COVAX)下,全球使用Covishield疫苗的途徑已經開啟。只有在疫苗的質量、安全性和有效性得到世衛組織的評估后,疫苗才能被投入緊急使用。

          疫苗第二和第三階段的測試結果在被列入世衛組織的緊急使用清單之前,由一個獨立小組和一個世衛組織專家小組進行了審查,審查用時一個月。據世衛組織稱,牛津和阿斯利康疫苗已在質量、安全性和有效性數據、風險管理計劃和必要的溫度管理適宜性方面獲得批準。

           

          Translated by Yan Jin

          Verified by Fu Xiao

           


          KATHMANDU, Feb 17: The Covishield vaccine currently being used in Nepal has been approved by the World Health organization (WHO). The organization on Monday allowed emergency use to Covishield, a vaccine being produced by the Serum Institute of India. This is one of two vaccines developed in collaboration with Oxford University and a pharmaceutical company, AstraZeneca.


          The WHO has also approved a vaccine manufactured by AstraZeneca and a South Korean company. Earlier on December 31, the WHO approved emergency use of the Pfizer vaccine. Prior to this, the organization approved emergency use of Pfizer vaccine on December 31. The 1 million dose Covishield vaccine provided by the Government of India to Nepal is produced by the Serum Institute of India. It was jointly developed by Oxford and AstraZeneca. The vaccine has been given to front-line health workers, cleaners and hospital staff in Nepal in the first phase from January 17, and then to journalists, staffers of UN agencies and diplomatic missions after the Department of Drug Administration gave permission for its emergency use in Nepal.


          The government has started vaccinating civil servants, elected representatives of local governments, employees of banks, health volunteers, ambulance drivers, hearses drivers and staff engaged in corpse management. It is preparing to inoculate senior citizens above the age of 55 from the second week of March at the community level. With the approval of the organization, the way to use Covishield vaccine worldwide under the COVAX facility has opened. The organization lists the vaccine in the Emergency Use List only after evaluating the quality, safety and effectiveness of the vaccine.


          The vaccines need to be included in the list before being supplied under the COVAX facility. The test results of the second and third phases of the vaccine were reviewed by an independent group and a team of WHO experts before being included in the organization's emergency use list. With the approval of the organization, it will be easier for general use. According to WHO, Oxford and AstraZeneca vaccines have been approved in terms of quality, safety and efficacy data, risk management plan and necessary temperature management suitability. The organization took four weeks to review this vaccine.


          Original Link:

          https://myrepublica.nagariknetwork.com/news/who-approves-emergency-use-of-covishield-vaccines-used-in-nepal/


          關閉

          97超人人澡高清碰碰,免费视频在线观看,日日摸夜夜摸狠狠摸,手机国产乱子伦精品视频,电影大全免费观看